|
| 36726222 | Measurement that matters: A systematic review and modified Delphi of multidisciplinary colorectal cancer quality indicators. | Asia Pac J Clin Oncol | 2024 |
| 36572991 | CCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study. | Cancer | 2023 |
| 37994114 | The use of intraperitoneal chemotherapy for advanced ovarian cancer - The experience of a tertiary referral centre. | Aust N Z J Obstet Gynaecol | 2023 |
| 36948887 | p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study. | J Pathol Clin Res | 2023 |
| 37452227 | Feasibility of Microlearning for Improving the Self-Efficacy of Cancer Patients Managing Side Effects of Chemotherapy. | J Cancer Educ | 2023 |
| 37286326 | Qualitative study of international key informants' perspectives on the current and future state of healthcare quality measurement and feedback. | BMJ Open | 2023 |
| 36785489 | Mainstream genetic testing for high-grade ovarian, tubal and peritoneal cancers: A tertiary referral centre experience. | Aust N Z J Obstet Gynaecol | 2023 |
| 36805919 | Older age should not be a barrier to testing for somatic variants in homologous recombination DNA repair-related genes in patients with high-grade serous ovarian carcinoma. | Transl Oncol | 2023 |
| 34782936 | MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma. | Virchows Arch | 2022 |
| 36612522 | A Systematic Review of Electronic Medical Record Driven Quality Measurement and Feedback Systems. | Int J Environ Res Public Health | 2022 |
| 36456881 | The genomic and immune landscape of long-term survivors of high-grade serous ovarian cancer. | Nat Genet | 2022 |
| 36222710 | Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes. | Clin Cancer Res | 2022 |
| 34853987 | Impact of the EndoPredict genomic assay on treatment decisions for oestrogen receptor-positive early breast cancer patients: benefits of physician selective testing. | Breast Cancer Res Treat | 2022 |
| 34897700 | Validated biomarker assays confirm that ARID1A loss is confounded with MMR deficiency, CD8<sup>+</sup> TIL infiltration, and provides no independent prognostic value in endometriosis-associated ovarian carcinomas. | J Pathol | 2022 |
| 34206826 | Maximum Tolerated Dose and Anti-Tumor Activity of Intraperitoneal Cantrixil (TRX-E-002-1) in Patients with Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer: Phase I Study Results. | Cancers (Basel) | 2021 |
| 33676492 | Improving Cancer MDT performance in Western Sydney - three years' experience. | BMC Health Serv Res | 2021 |
| 34636747 | New therapeutic opportunities for women with low-grade serous ovarian cancer. | Endocr Relat Cancer | 2021 |
| 34649110 | Developing a maturity model for cancer multidisciplinary teams. | Int J Med Inform | 2021 |
| 32314968 | Developing an Intranet-Based Lymphedema Dashboard for Breast Cancer Multidisciplinary Teams: Design Research Study. | J Med Internet Res | 2020 |
| 32473302 | Prognostic gene expression signature for high-grade serous ovarian cancer. | Ann Oncol | 2020 |
| 30927464 | Attitudes of health professionals to using routinely collected clinical data for performance feedback and personalised professional development. | Med J Aust | 2019 |
| 31239549 | A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases. | Mod Pathol | 2019 |
| 31378459 | Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial. | Lancet Oncol | 2019 |
| 31259279 | A tool to improve the performance of multidisciplinary teams in cancer care. | BMJ Open Qual | 2019 |
| 29061645 | Homologous Recombination DNA Repair Pathway Disruption and Retinoblastoma Protein Loss Are Associated with Exceptional Survival in High-Grade Serous Ovarian Cancer. | Clin Cancer Res | 2018 |
| 35135122 | <i>BRAF</i> Mutations in Low-Grade Serous Ovarian Cancer and Response to BRAF Inhibition. | JCO Precis Oncol | 2018 |
| 29807697 | Response rates to second-line platinum-based therapy in ovarian cancer patients challenge the clinical definition of platinum resistance. | Gynecol Oncol | 2018 |
| 30013673 | Improved ovarian cancer EMT-CTC isolation by immunomagnetic targeting of epithelial EpCAM and mesenchymal N-cadherin. | J Circ Biomark | 2018 |
| 30062862 | Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study. | J Pathol Clin Res | 2018 |
| 29898716 | Multidisciplinary teams and ICT: a qualitative study exploring the use of technology and its impact on multidisciplinary team meetings. | BMC Health Serv Res | 2018 |
| 29502561 | MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. | Mayo Clin Proc | 2018 |
| 29367611 | Genome-wide association study of paclitaxel and carboplatin disposition in women with epithelial ovarian cancer. | Sci Rep | 2018 |
| 29531130 | Transducin-Like Enhancer of Split 3 (TLE3) Expression Is Associated with Taxane Sensitivity in Nonserous Ovarian Carcinoma in a Three-Cohort Study. | Cancer Epidemiol Biomarkers Prev | 2018 |
| 27372543 | Embedding continuous quality improvement processes in multidisciplinary teams in cancer care: exploring the boundaries between quality and implementation science. | Aust Health Rev | 2017 |
| 28407011 | Anthracyclines induce early changes in left ventricular systolic and diastolic function: A single centre study. | PLoS One | 2017 |
| 28214405 | Our Faustian pact with the digital world. | Lancet Oncol | 2017 |
| 29049607 | Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer. | JAMA Oncol | 2017 |
| 28646021 | <i>EIF1AX</i> and <i>NRAS</i> Mutations Co-occur and Cooperate in Low-Grade Serous Ovarian Carcinomas. | Cancer Res | 2017 |
| 27798749 | A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN study. | Breast Cancer Res Treat | 2017 |
| 26968519 | A mixed methods approach to developing and evaluating oncology trainee education around minimization of adverse events and improved patient quality and safety. | BMC Med Educ | 2016 |
| 27503206 | An Online Learning Module to Increase Self-Efficacy and Involvement in Care for Patients With Advanced Lung Cancer: Research Protocol. | JMIR Res Protoc | 2016 |
| 27235952 | Patterns and trends in the incidence of paediatric and adult germ cell tumours in Australia, 1982-2011. | Cancer Epidemiol | 2016 |
| 27444035 | Serous ovarian and primary peritoneal cancers: A comparative analysis of clinico-pathological features, molecular subtypes and treatment outcome. | Gynecol Oncol | 2016 |
| 26840454 | Germline polymorphisms in an enhancer of PSIP1 are associated with progression-free survival in epithelial ovarian cancer. | Oncotarget | 2016 |
| 24531715 | Inhibition of ANKRD1 sensitizes human ovarian cancer cells to endoplasmic reticulum stress-induced apoptosis. | Oncogene | 2015 |
| 26503049 | Corrigendum: Whole-genome characterization of chemoresistant ovarian cancer. | Nature | 2015 |
| 26017449 | Whole-genome characterization of chemoresistant ovarian cancer. | Nature | 2015 |
| 24318743 | Weekly AUC2 carboplatin in acquired platinum-resistant ovarian cancer with or without oral phenoxodiol, a sensitizer of platinum cytotoxicity: the phase III OVATURE multicenter randomized study. | Ann Oncol | 2014 |
| 25316818 | Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver. | Clin Cancer Res | 2014 |
| 25169081 | Retrospective imaging audit and cost analysis of medical oncology inpatients admitted to Westmead Hospital. | Intern Med J | 2014 |